Search

Your search keyword '"Venter, Willem"' showing total 541 results
Start Over Author "Venter, Willem"
541 results on '"Venter, Willem"'

52. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Author

Bosch, Bronwyn, primary, Akpomiemie, Godspower, additional, Chandiwana, Nomathemba, additional, Sokhela, Simiso, additional, Hill, Andrew, additional, McCann, Kaitlyn, additional, Qavi, Ambar, additional, Mirchandani, Manya, additional, and Venter, Willem Daniel Francois, additional

Published
2022
Full Text
View/download PDF

53. Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

Author

Chandiwana, Nomathemba, primary, Kruger, Chelsea, additional, Johnstone, Hilary, additional, Chughlay, Mohamed Farouk, additional, Ju, Chung, additional, Kim, Byungsu, additional, Dineka, Yengiwe, additional, Arbe-Barnes, Sarah, additional, Miller, Robert, additional, Owen, Andrew, additional, Hill, Andrew, additional, Windgassen, Daniel, additional, Abla, Nada, additional, Marrast, Anne Claire, additional, Duparc, Stephan, additional, and Francois Venter, Willem Daniel, additional

Published
2022
Full Text
View/download PDF

54. Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa

Author

Sokhela, Simiso, primary, Bosch, Bronwyn, additional, Hill, Andrew, additional, Simmons, Bryony, additional, Woods, Joana, additional, Johnstone, Hilary, additional, Madhi, Shabir, additional, Qavi, Ambar, additional, Ellis, Leah, additional, Akpomiemie, Godspower, additional, Bhaskar, Esther, additional, Levi, Jacob, additional, Falconer, Jonathan, additional, Mirchandani, Manya, additional, Perez Casas, Carmen, additional, Moller, Karlien, additional, Pilkington, Victoria, additional, Pepperrell, Toby, additional, and Venter, Willem Daniel Francois, additional

Published
2022
Full Text
View/download PDF

57. A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch

Author

Hermans, Lucas E., primary, Ter Heine, Rob, additional, Schuurman, Rob, additional, Tempelman, Hugo A., additional, Burger, David M., additional, Vervoort, Sigrid C.J.M., additional, Deville, Walter L.J.M., additional, De Jong, Dorien, additional, Venter, Willem D.F., additional, Nijhuis, Monique, additional, and Wensing, Annemarie M.J., additional

Published
2022
Full Text
View/download PDF

62. Comparative performance of cardiovascular risk prediction models in people living with HIV

Author

Global Health team 1, Epi Methoden Team 5, MS Interne Geneeskunde, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Tahir, Irtiza, Vos, Alinda, Damen, Johanna, Barth, Roos, Tempelman, Hugo, Grobbee, Diederick, Scheuermaier, Karine, Venter, Willem, Klipstein-Grobusch, Kerstin, Global Health team 1, Epi Methoden Team 5, MS Interne Geneeskunde, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Tahir, Irtiza, Vos, Alinda, Damen, Johanna, Barth, Roos, Tempelman, Hugo, Grobbee, Diederick, Scheuermaier, Karine, Venter, Willem, and Klipstein-Grobusch, Kerstin

Published
2022

63. HIV-1 pretreatment drug resistance negatively impacts outcomes of first-line antiretroviral treatment

Author

Clinical Virology, Medische Microbiologie, MMB Research line 3b, MMB Staf diagnostiek, Infection & Immunity, MMB, Divisieleiding, MMB Research line 3a, MMB opleiding Arts microbioloog, Hermans, Lucas E., Hofstra, Laura M., Schuurman, Rob, Ter Heine, Rob, Burger, David M., Talboom, Stijn A.J., De Jong, Dorien, Tempelman, Hugo A., Venter, Willem D.F., Nijhuis, Monique, Wensing, Annemarie M.J., Clinical Virology, Medische Microbiologie, MMB Research line 3b, MMB Staf diagnostiek, Infection & Immunity, MMB, Divisieleiding, MMB Research line 3a, MMB opleiding Arts microbioloog, Hermans, Lucas E., Hofstra, Laura M., Schuurman, Rob, Ter Heine, Rob, Burger, David M., Talboom, Stijn A.J., De Jong, Dorien, Tempelman, Hugo A., Venter, Willem D.F., Nijhuis, Monique, and Wensing, Annemarie M.J.

Published
2022

64. A randomized study of intensified antiretroviral treatment monitoring versus standard-of-care for prevention of drug resistance and antiretroviral treatment switch: week 96 results of the ITREMA trial

Author

Clinical Virology, Medische Microbiologie, MMB Staf diagnostiek, Infection & Immunity, Divisieleiding, Verplegingswetenschap, Cancer, Global Health, MMB, MMB Research line 3a, Hermans, Lucas E., Ter Heine, Rob, Schuurman, Rob, Tempelman, Hugo A., Burger, David M., Vervoort, Sigrid C.J.M., Deville, Walter L.J.M., De Jong, Dorien, Venter, Willem D.F., Nijhuis, Monique, Wensing, Annemarie M.J., Clinical Virology, Medische Microbiologie, MMB Staf diagnostiek, Infection & Immunity, Divisieleiding, Verplegingswetenschap, Cancer, Global Health, MMB, MMB Research line 3a, Hermans, Lucas E., Ter Heine, Rob, Schuurman, Rob, Tempelman, Hugo A., Burger, David M., Vervoort, Sigrid C.J.M., Deville, Walter L.J.M., De Jong, Dorien, Venter, Willem D.F., Nijhuis, Monique, and Wensing, Annemarie M.J.

Published
2022

65. Corrigendum: The influence of HIV infection and antiretroviral treatment on pulmonary function in individuals in an urban setting in sub-Saharan Africa

Author

MS Interne Geneeskunde, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Global Health team 1, van den Berg, Oda E., Shaddock, Erica J., Stacey, Sarah L., Feldman, Charles, Barth, Roos E., Grobbee, Diederick E., Venter, Willem D.F., Klipstein-Grobusch, Kerstin, Vos, Alinda G., MS Interne Geneeskunde, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Global Health team 1, van den Berg, Oda E., Shaddock, Erica J., Stacey, Sarah L., Feldman, Charles, Barth, Roos E., Grobbee, Diederick E., Venter, Willem D.F., Klipstein-Grobusch, Kerstin, and Vos, Alinda G.

Published
2022

66. The influence of smoking and HIV infection on pulmonary function

Author

Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Global Health team 1, Sussenbach, Annelotte, Gijzel, Sjors van, Lalla-Edward, Samanta, Venter, Willem, Shaddock, Erica, Feldman, Charles, Klipstein-Grobusch, Kerstin, Vos, Alinda, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Global Health team 1, Sussenbach, Annelotte, Gijzel, Sjors van, Lalla-Edward, Samanta, Venter, Willem, Shaddock, Erica, Feldman, Charles, Klipstein-Grobusch, Kerstin, and Vos, Alinda

Published
2022

68. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya

Author

Rosen, Sydney, Maskew, Mhairi, Larson, Bruce A., Brennan, Alana T., Tsikhutsu, Isaac, Fox, Matthew P., Vezi, Lungisile, Bii, Margaret, and Venter, Willem D. F.

Subjects
Clinical trials -- Analysis, HIV infections -- Care and treatment, Antiretroviral agents -- Usage, Algorithms, Medical examination, Medical personnel, HIV, AIDS treatment, Public health, Ambulatory care facilities, Biological sciences
Abstract

Background The World Health Organization recommends 'same-day' initiation of antiretroviral therapy (ART) for HIV patients who are eligible and ready. Identifying efficient, safe, and feasible procedures for determining same-day eligibility and readiness is now a priority. The Simplified Algorithm for Treatment Eligibility (SLATE) study evaluated a clinical algorithm that allows healthcare workers to determine eligibility for same-day treatment and to initiate ART at the patient's first clinic visit. Methods and findings SLATE was an individually randomized trial at three outpatient clinics in urban settlements in Johannesburg, South Africa and three hospital clinics in western Kenya. Adult, nonpregnant, HIV-positive, ambulatory patients presenting for any HIV care, including HIV testing, but not yet on ART were enrolled and randomized to the SLATE algorithm arm or standard care. The SLATE algorithm used four screening tools-a symptom self-report, medical history questionnaire, physical examination, and readiness assessment-to ascertain eligibility for same-day initiation or refer for further care. Follow-up was by record review, and analysis was conducted by country. We report primary outcomes of 1) ART initiation [less than or equal to]28 days and 2) initiation [less than or equal to]28 days and retention in care [less than or equal to]8 months of enrollment. From March 7, 2017 to April 17, 2018, we enrolled 600 patients (median [IQR] age 34 [29-40] and CD4 count 286 [128-490]; 63% female) in South Africa and 477 patients in Kenya (median [IQR] age 35 [29-43] and CD4 count 283 [117-541]; 58% female). In the intervention arm, 78% of patients initiated [less than or equal to]28 days in South Africa, compared to 68% in the standard arm (risk difference [RD] [95% confidence interval (CI)] 10% [3%-17%]); in Kenya, 94% of intervention-arm patients initiated [less than or equal to]28 days compared to 89% in the standard arm (6% [0.5%-11%]). By 8 months in South Africa, 161/298 (54%) intervention-arm patients had initiated and were retained, compared to 146/302 (48%) in the standard arm (6% [(2% to 14%]). By 8 months in Kenya, the corresponding retention outcomes were identical in both arms (137/240 [57%] of intervention-arm patients and 136/237 [57%] of standard-arm patients). Limitations of the trial included limited geographic representativeness, exclusion of patients too ill to participate, missing viral load data, greater study fidelity to the algorithm than might be achieved in standard care, and secular changes in standard care over the course of the study. Conclusions In South Africa, the SLATE algorithm increased uptake of ART within 28 days by 10% and showed a numerical increase (6%) in retention at 8 months. In Kenya, the algorithm increased uptake of ART within 28 days by 6% but found no difference in retention at 8 months. Eight-month retention was poor in both arms and both countries. These results suggest that a simple structured algorithm for same-day treatment initiation procedures is feasible and can increase and accelerate ART uptake but that early retention on treatment remains problematic. Trial registration Clinicaltrials.gov NCT02891135, registered September 1, 2016. First participant enrolled March 6, 2017 in South Africa and July 13, 2017 in Kenya., Author(s): Sydney Rosen 1,2,*, Mhairi Maskew 2, Bruce A. Larson 1, Alana T. Brennan 1,2,3, Isaac Tsikhutsu 4,5, Matthew P. Fox 1,2,3, Lungisile Vezi 2, Margaret Bii 4,5, Willem D. [...]

Published
2019
Full Text
View/download PDF

69. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.

Author

Bosch, Bronwyn, Akpomiemie, Godspower, Chandiwana, Nomathemba, Sokhela, Simiso, Hill, Andrew, McCann, Kaitlyn, Qavi, Ambar, Mirchandani, Manya, and Venter, Willem Daniel Francois

Subjects
LIPID analysis, ENERGY metabolism, HIV infections, GLYCOSYLATED hemoglobin, BLOOD pressure, BODY weight, COMBINATION drug therapy, GENERIC drug substitution, TENOFOVIR, DESCRIPTIVE statistics, HIGH density lipoproteins, BODY mass index, STATISTICAL sampling, EMTRICITABINE
Abstract

Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

70. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.

Author

Hermans, Lucas E, Umunnakwe, Chijioke N, Lalla-Edward, Samanta T, Hebel, Shane K, Tempelman, Hugo A, Nijhuis, Monique, Venter, Willem D F, and Wensing, Annemarie M J

Subjects
HIV infections, ANTI-HIV agents, EFAVIRENZ, CONFIDENCE intervals, SEQUENCE analysis, POINT-of-care testing, TENOFOVIR, DRUG resistance, ANTIRETROVIRAL agents, CASE-control method, TREATMENT failure, PRE-exposure prophylaxis, RESEARCH funding, URINALYSIS, PREDICTION models, SENSITIVITY & specificity (Statistics), ODDS ratio, EMTRICITABINE
Abstract

Background Viral rebound during antiretroviral treatment (ART) is most often driven by suboptimal adherence in the absence of drug resistance. We assessed the diagnostic performance of point-of-care (POC) tenofovir (TFV) detection in urine for the prediction of viral rebound and drug resistance during ART. Methods We performed a nested case-control study within the ADVANCE randomized clinical trial (NCT03122262) in Johannesburg, South Africa. Adults with human immunodeficiency virus (HIV) and newly initiating ART were randomized to receive either dolutegravir or efavirenz, tenofovir disoproxil fumarate or alafenamide, and emtricitabine. All participants with rebound ≥200 copies/mL between 24 and 96 weeks of follow-up were selected as cases and matched to controls with virological suppression <50 copies/mL. Rapid POC urine-TFV detection was performed retrospectively. Results We included 281 samples from 198 participants. Urine-TFV was detectable in 30.7% (70/228) of cases and in 100% (53/53) of controls. Undetectable urine-TFV predicted rebound with a sensitivity of 69% [95% confidence interval {CI}: 63–75] and specificity of 100% [93–100]. In cases with virological failure and sequencing data (n = 42), NRTI drug resistance was detected in 50% (10/20) of cases with detectable urine-TFV versus in 8.3% (2/24) of cases with undetectable urine-TFV. Detectable urine-TFV predicted NRTI resistance (odds ratio [OR] 10.4 [1.8–114.4] P =.005) with a sensitivity of 83% [52–98] and specificity of 69% [50–84]. Conclusions POC objective adherence testing using a urine-TFV test predicted viral rebound with high specificity. In participants with rebound, urine-TFV testing predicted the selection of drug resistance. Objective adherence testing may be used to rapidly provide insight into adherence, suppression, and drug resistance during ART. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

73. From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With HIV in Low- and Middle-Income Settings.

Author

Manne-Goehler, Jennifer, Ali, Mohammed K, Flood, David, Marconi, Vincent C, Venter, Willem D F, and Siedner, Mark J

Subjects
POLITICAL psychology, DIABETES risk factors, CARDIOVASCULAR disease prevention, MIDDLE-income countries, RISK assessment, ANTILIPEMIC agents, EVIDENCE gaps, PREDICTION models, HIV-positive persons, MEDICAL care, CARDIOVASCULAR diseases risk factors, STATINS (Cardiovascular agents), PUBLIC health, LOW-income countries, OBESITY
Abstract

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found a 35% reduction in major adverse cardiovascular events for people with human immunodeficiency virus who received daily pitavastatin. However, how this evidence will change practice is far from certain. Here, we outline evidence gaps and political and healthcare delivery challenges that will need to be addressed for REPRIEVE to offer public health benefits in low- and middle-income countries. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

76. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz

Author

Asif, Sumbul, primary, Baxevanidi, Evangelia, additional, Hill, Andrew, additional, Venter, Willem Daniel Francois, additional, Fairlie, Lee, additional, Masenya, Masebole, additional, Serenata, Celicia, additional, Sokhela, Simiso, additional, and Chandiwana, Nomathemba, additional

Published
2021
Full Text
View/download PDF

79. Southern African HIV Clinicians Society 2023 Guideline for post-exposure prophylaxis: Updated recommendations.

Author

Horak, Jaco, Venter, Willem D.F., Wattrus, Camilla, Papavarnavas, Nectarios, Howell, Pauline, Sorour, Gillian, Wallis, Carole, Gill, Katherine, Conradie, Francesca, and Bekker, Linda-Gail

Subjects
*HIV seroconversion, *HEPATITIS B, *MEDICAL personnel, *HIV
Abstract

The Southern African HIV Clinicians Society has released updated recommendations for post-exposure prophylaxis (PEP) in their 2023 guideline. PEP is a preventive intervention that involves administering antiretroviral therapy to an HIV-negative person who has been exposed to the virus. The guideline provides a stepwise approach to providing PEP, including prevention of exposure, initial assessment following exposure, and appropriate counseling and support. It also discusses the risk of transmission in different settings and emphasizes the importance of adherence to the full 28-day course of treatment. The document also addresses considerations for other health conditions related to exposure and provides recommendations for follow-up counseling and referral for individuals experiencing anxiety and trauma. [Extracted from the article]

Published
2023
Full Text
View/download PDF

80. Designing a new methodology for customs risk models

Author

10196978 - Hoffman, Alwyn Jakobus, 10063218 - Venter, Willem Christiaan, 11929448 - Grater, Sonja, Hoffman, Alwyn, Grater, Sonja, Venter, Willem C., Maree, Juanita, Liebenberg, David, 10196978 - Hoffman, Alwyn Jakobus, 10063218 - Venter, Willem Christiaan, 11929448 - Grater, Sonja, Hoffman, Alwyn, Grater, Sonja, Venter, Willem C., Maree, Juanita, and Liebenberg, David

Abstract

Effective risk management is a prerequisite to find an acceptable balance between the objectives of a customs operation and the streamlined flow of goods. The customs operations in many developing countries are characterised by high levels of physical inspections, with resulting disruption of trade flows, but with little positive impact for the regional economy. Most developed economies have moved towards customs risk management models based on the analysis of rich datasets that can be used to accurately determine the risk represented by a cargo consignment without physically stopping it. The use of such models can result in reduced physical inspections without increasing the risk to Customs of either losing income or allowing the influx of illegal contraband. It, therefore, represents a more optimal compromise between the interests of customs and those of trade, reducing the economic cost to the region and making the region more attractive to global economic partners. In this paper we develop a rigorous methodology that utilises electronic data transacted between Customs and trade to characterise the risk attributes of cargo consignments and then extract a model that can be applied in real time to minimise disruption of trade flows while reducing Customs risks to levels that are below set thresholds. This paper builds on previous work of Laporte (2011) and others but extends their results by developing a more detailed methodology to quantify the impact of a variety of input factors and demonstrating how an optimal set of inputs can be selected to arrive at an effective risk management model

Published
2019

82. Southern African HIV Clinicians Society gender-affirming healthcare guideline for South Africa

Author

Tomson, Anastacia, primary, McLachlan, Christine, additional, Wattrus, Camilla, additional, Adams, Kevin, additional, Addinall, Ronald, additional, Bothma, Rutendo, additional, Jankelowitz, Lauren, additional, Kotze, Elliott, additional, Luvuno, Zamasomi, additional, Madlala, Nkanyiso, additional, Matyila, Savuka, additional, Padavatan, Anil, additional, Pillay, Mershen, additional, Rakumakoe, Mmamontsheng D., additional, Tomson-Myburgh, Mathilde, additional, Venter, Willem D.F., additional, and De Vries, Elma, additional

Published
2021
Full Text
View/download PDF

87. Study protocol: Strengthening understanding of effective adherence strategies for first-line and second-line antiretroviral therapy (ART) in selected rural and urban communities in South Africa

Author

Leerstoel de Wit, Social Policy and Public Health, Gumede, Siphamandla Bonga, de Wit, John Benjamin Frank, Venter, Willem Daniel Francois, Lalla-Edward, Samanta Tresha, Leerstoel de Wit, Social Policy and Public Health, Gumede, Siphamandla Bonga, de Wit, John Benjamin Frank, Venter, Willem Daniel Francois, and Lalla-Edward, Samanta Tresha

Published
2021

88. The influence of HIV infection and antiretroviral treatment on pulmonary function in individuals in an urban setting in sub-Saharan Africa

Author

MS Interne Geneeskunde, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Global Health team 1, Unit Opleiding Aios, Berg, Oda E.Van Den, Shaddock, Erica J., Stacey, Sarah L., Feldman, Charles, Barth, Roos E., Grobbee, Diederick E., Venter, Willem D.F., Klipstein-Grobusch, Kerstin, Vos, Alinda G., MS Interne Geneeskunde, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Global Health team 1, Unit Opleiding Aios, Berg, Oda E.Van Den, Shaddock, Erica J., Stacey, Sarah L., Feldman, Charles, Barth, Roos E., Grobbee, Diederick E., Venter, Willem D.F., Klipstein-Grobusch, Kerstin, and Vos, Alinda G.

Published
2021

89. Predictors of impaired pulmonary function in people living with HIV in an urban African setting

Author

Arts-assistenten Radiologie, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Global Health team 1, Unit Opleiding Aios, Van Riel, Sarah E., Klipstein-Grobusch, Kerstin, Barth, Roos E., Grobbee, Diederick E., Feldman, Charles, Shaddock, Erica, Stacey, Sarah L., Venter, Willem D.F., Vos, Alinda G., Arts-assistenten Radiologie, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Global Health team 1, Unit Opleiding Aios, Van Riel, Sarah E., Klipstein-Grobusch, Kerstin, Barth, Roos E., Grobbee, Diederick E., Feldman, Charles, Shaddock, Erica, Stacey, Sarah L., Venter, Willem D.F., and Vos, Alinda G.

Published
2021

91. Designing a new methodology for customs risk models

Author

Hoffman, Alwyn, Grater, Sonja, Venter, Willem C., Maree, Juanita, Liebenberg, David, 10196978 - Hoffman, Alwyn Jakobus, 10063218 - Venter, Willem Christiaan, and 11929448 - Grater, Sonja

Abstract

Effective risk management is a prerequisite to find an acceptable balance between the objectives of a customs operation and the streamlined flow of goods. The customs operations in many developing countries are characterised by high levels of physical inspections, with resulting disruption of trade flows, but with little positive impact for the regional economy. Most developed economies have moved towards customs risk management models based on the analysis of rich datasets that can be used to accurately determine the risk represented by a cargo consignment without physically stopping it. The use of such models can result in reduced physical inspections without increasing the risk to Customs of either losing income or allowing the influx of illegal contraband. It, therefore, represents a more optimal compromise between the interests of customs and those of trade, reducing the economic cost to the region and making the region more attractive to global economic partners. In this paper we develop a rigorous methodology that utilises electronic data transacted between Customs and trade to characterise the risk attributes of cargo consignments and then extract a model that can be applied in real time to minimise disruption of trade flows while reducing Customs risks to levels that are below set thresholds. This paper builds on previous work of Laporte (2011) and others but extends their results by developing a more detailed methodology to quantify the impact of a variety of input factors and demonstrating how an optimal set of inputs can be selected to arrive at an effective risk management model

Published
2019

94. Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial

Author

Pepperrell, Toby, primary, Venter, Willem Daniel Francois, additional, McCann, Kaitlyn, additional, Bosch, Bronwyn, additional, Tibbatts, Melissa, additional, Woods, Joanna, additional, Sokhela, Simiso, additional, Serenata, Celicia, additional, Moorhouse, Michelle, additional, Qavi, Ambar, additional, and Hill, Andrew, additional

Published
2021
Full Text
View/download PDF

95. Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study

Author

MMB Research line 3b, MMB Research line 3a, Infection & Immunity, Divisieleiding, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 9, MMB opleiding Arts microbioloog, Hermans, Lucas E, Carmona, Sergio, Nijhuis, Monique, Tempelman, Hugo A, Richman, Douglas D, Moorhouse, Michelle, Grobbee, Diederick E, Venter, Willem D F, Wensing, Annemarie M J, MMB Research line 3b, MMB Research line 3a, Infection & Immunity, Divisieleiding, Global Health, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Cardiovasculaire Epi Team 9, MMB opleiding Arts microbioloog, Hermans, Lucas E, Carmona, Sergio, Nijhuis, Monique, Tempelman, Hugo A, Richman, Douglas D, Moorhouse, Michelle, Grobbee, Diederick E, Venter, Willem D F, and Wensing, Annemarie M J

Published
2020

96. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

Author

Global Health team 1, Unit Opleiding Aios, Venter, Willem D F, Sokhela, Simiso, Simmons, Bryony, Moorhouse, Michelle, Fairlie, Lee, Mashabane, Nkuli, Serenata, Celicia, Akpomiemie, Godspower, Masenya, Masebole, Qavi, Ambar, Chandiwana, Nomathemba, McCann, Kaitlyn, Norris, Shane, Chersich, Matthew, Maartens, Gary, Lalla-Edward, Samanta, Vos, Alinda, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, Hill, Andrew, Global Health team 1, Unit Opleiding Aios, Venter, Willem D F, Sokhela, Simiso, Simmons, Bryony, Moorhouse, Michelle, Fairlie, Lee, Mashabane, Nkuli, Serenata, Celicia, Akpomiemie, Godspower, Masenya, Masebole, Qavi, Ambar, Chandiwana, Nomathemba, McCann, Kaitlyn, Norris, Shane, Chersich, Matthew, Maartens, Gary, Lalla-Edward, Samanta, Vos, Alinda, Clayden, Polly, Abrams, Elaine, Arulappan, Natasha, and Hill, Andrew

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results